TR-701 FA + Linezolid
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Skin and Subcutaneous Tissue Bacterial Infections
Conditions
Skin and Subcutaneous Tissue Bacterial Infections
Trial Timeline
Aug 15, 2010 → Sep 30, 2011
NCT ID
NCT01170221About TR-701 FA + Linezolid
TR-701 FA + Linezolid is a phase 3 stage product being developed by Merck for Skin and Subcutaneous Tissue Bacterial Infections. The current trial status is completed. This product is registered under clinical trial identifier NCT01170221. Target conditions include Skin and Subcutaneous Tissue Bacterial Infections.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01421511 | Phase 3 | Completed |
| NCT01170221 | Phase 3 | Completed |
Competing Products
20 competing products in Skin and Subcutaneous Tissue Bacterial Infections